OTCMKTS:VAXX Vaxxinity Q4 2023 Earnings Results & Report $0.02 +0.01 (+14,900.00%) As of 11/2/2026 10:26 AM Eastern Vaxxinity beat analyst earnings expectations in its Q4 2023 results, released March 27, 2024. The company reported EPS of -$0.09 versus the -$0.13 consensus estimate. Research:Profile Earnings Announcement Details QuarterQ4 2023Report DateMarch 27, 2024 Vaxxinity EPS ResultsActual EPS-$0.09Consensus EPS -$0.13Beat/MissBeat by +$0.04One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersVaxxinity Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsVaxxinity's next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile Vaxxinity Q4 2023 Earnings FAQ Did Vaxxinity beat earnings estimates for Q4 2023? Vaxxinity (OTCMKTS:VAXX) reported earnings of -$0.09 per share for Q4 2023, beating the consensus estimate of -$0.13. The report was announced on Wednesday, March 27, 2024. When is Vaxxinity's next earnings date? Vaxxinity's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Vaxxinity on the company's earnings history page. Vaxxinity Earnings HeadlinesVaxxinity (OTCMKTS:VAXX) Shares Cross Above Two Hundred Day Moving Average - Here's What HappenedOctober 27, 2026 | americanbankingnews.comVaxxinity Inc.May 25, 2026 | marketwatch.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | Decentralized Masters (Ad)Brain healthOctober 24, 2024 | newsweek.comNTreatment Trials in Alzheimer's DiseaseSeptember 30, 2024 | msn.comVaxxinity UB-312 Parkinson's Trial Results Published in Nature MedicineJune 20, 2024 | globenewswire.comSee More Vaxxinity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxxinity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxxinity and other key companies, straight to your email. Email Address About VaxxinityVaxxinity (OTCMKTS:VAXX) Inc. is a biotechnology company focused on developing vaccines and immunotherapies for chronic diseases, including neurodegenerative conditions. The company’s approach is designed to stimulate the body’s immune system to target disease-related proteins or pathways, with the goal of addressing underlying disease biology rather than treating symptoms alone. Vaxxinity’s research and development pipeline has included UB-311, an investigational vaccine targeting amyloid beta for Alzheimer’s disease, and UB-312, an investigational vaccine designed to target abnormal alpha-synuclein associated with Parkinson’s disease and other synucleinopathies. The company has also pursued programs in other chronic conditions, including migraine and metabolic or endocrine disorders. These products remain investigational and are subject to clinical testing and regulatory review. The company was formerly known as United Neuroscience and adopted the Vaxxinity name as it broadened its focus on immune-based medicines. Vaxxinity is headquartered in the United States and has conducted development activities through international clinical and research collaborations. Mei Mei Hu, a co-founder of the company, has served as its chief executive officer.View Vaxxinity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another TestAlphabet’s $400 Billion Sell-Off Could Be the Best AI Buying Window Left in 2026Exxon's Refining Profits Soared—Did Chevron Get the Same Windfall?LyondellBasell's Dividend Looks Safer, But a New Risk Could Change ThatUranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Silicon Shock: Intel's 25% Valuation Reset Upcoming Earnings Booking (11/3/2026)Ferrari (11/3/2026)Marathon Petroleum (11/3/2026)Mplx (11/3/2026)Suncor Energy (11/3/2026)Apollo Global Management (11/3/2026)Itau Unibanco (11/3/2026)Amgen (11/3/2026)Pfizer (11/3/2026)Eaton (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
